REGENEREX PHARMA, INC. Income Statement

Ask AI

Financial Statements

In USD, except per-share amounts

	FY2024 12 months to Mar 31, 2025	FY2023 12 months to Mar 31, 2024	FY2022 12 months to Mar 31, 2023	FY2021 12 months to Mar 31, 2022	FY2020 12 months to Mar 31, 2021
Sales
Goods sold
Provision for write down of inventory
Total Cost of Sales
Gross Profit (Loss)
Operating Expenses:
General and administrative
Sales and marketing
Research and development

Total Operating Expenses
Operating Gain (Loss)
Other Income (Expense):
Interest expense
Foreign currency gain
Loss from theft
Taxes
Total Other Income (Expense)
Loss from Continuing Operations
Loss from Discontinued Operations
Net Loss
Basic and Diluted Loss per Common Share – Continuing Operations
Basic and Diluted Loss per Common Share
Basic and Diluted Loss per Common Share – Discontinued Operations
Weighted Average Number of Common Shares Outstanding

Comments